First-Line Pd-1/Pd-L1 Inhibitor Followed By Carboplatin (Carbo)-Based Chemotherapy (Chemo) Or The Reverse Sequence In Cisplatin-Ineligible Metastatic Urothelial Cancer (Muc) Patients (Pts).

e16517Background: PD-1/PD-L1 inhibitors or carbo-based chemo are both reasonable therapeutic options in the first-line setting for cisplatin-ineligible mUC pts. However, optimal first-line therapy and sequencing of these regimens is unclear. Methods: We conducted a multicenter retrospective analysis of cisplatin-ineligible mUC pts treated with first-line PD-1/PD-L1 monotherapy followed by carbo-based chemo (P- u003e C) or the reverse order (C- u003e P). Perioperative cisplatin-based chemo was allowed if the interval between its completion and starting first-line mUC therapy was u003e 1 year. A multivariate analysis (MVA) examined the association of sequence of therapy with overall survival (OS) adjusted for baseline Hb ( C n = 33, C- u003e P n = 82) with median age 71, 74% men, and 85% ECOG PS 0-1 were included. Most pts (94.8%) had not received prior perioperative cisplatin-based chemo,...